Please enable JavaScript to continue using this application.

Compare $TNXP vs $VTVT | Chartloom

Compare

$TNXP vs $VTVT

Tonix Pharmaceuticals Holding Corp · vTv Therapeutics Inc

TNXP

Tonix Pharmaceuticals Holding Corp

VTVT

vTv Therapeutics Inc

Compare $TNXP vs $VTVT

Comparing Tonix Pharmaceuticals Holding Corp and vTv Therapeutics Inc

TNXPTonix Pharmaceuticals Holding Corp

VTVTvTv Therapeutics Inc

TNXPTonix Pharmaceuticals Holding Corp

Market cap

$116M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.39x

Rev growth (TTM)

196.0%

YTD performance

-55.9%

52W performance

-67.5%

FCF yield

-135.9%

VTVTvTv Therapeutics Inc

Market cap

$123M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

216600.0%

YTD performance

-21.3%

52W performance

38.3%

FCF yield

-13.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

TNXP

VTVT

Detailed metrics comparison

TNXP

Tonix Pharmaceuticals Holding Corp

VTVT

vTv Therapeutics Inc

Market Cap

TNXP$116M

VTVT$123M

Enterprise Value

TNXP$-60M

VTVT$36M

Price

TNXP$7.30

VTVT$31.18

P/E Ratio

TNXPN/A

VTVTN/A

P/S Ratio

TNXP4.00x

VTVT3.33x

EV/Sales

TNXP-2.06x

VTVT0.98x

EV/EBITDA

TNXP0.00x

VTVT0.00x

P/B Ratio

TNXP0.69x

VTVT1.53x

P/FCF Ratio

TNXPN/A

VTVTN/A

EV/FCF

TNXP0.38x

VTVT-2.16x

PEG Ratio

TNXPN/A

VTVTN/A

Forward P/E (NTM)

TNXPN/A

VTVTN/A

Forward P/S (NTM)

TNXP1.39x

VTVTN/A

Revenue (TTM)

TNXP$29M

VTVT$37M

Revenue Growth (YoY)

TNXP196.0%

VTVT216600.0%

Forward Rev Growth

TNXP101.6%

VTVT-97.3%

Gross Margin (TTM)

TNXP83.8%

VTVT0.0%

Operating Margin (TTM)

TNXP0.0%

VTVT63.1%

EBITDA Margin (TTM)

TNXP-561.1%

VTVT-25.1%

Net Margin (TTM)

TNXP-548.6%

VTVT-12.9%

FCF Margin (TTM)

TNXP-543.3%

VTVT-45.5%

Net Income (TTM)

TNXP$-160M

VTVT$-5M

FCF (TTM)

TNXP$-158M

VTVT$-17M

EPS (TTM)

TNXP-$9.60

VTVT-$0.38

ROE (TTM)

TNXP-6899.0%

VTVT-627.0%

ROA (TTM)

TNXP-6132.0%

VTVT-506.0%

ROIC (TTM)

TNXP-6899.0%

VTVT-626.0%

Cash

TNXP$176M

VTVT$87M

Debt

TNXP$0

VTVT$0

Net Cash/Debt

TNXP$176M

VTVT$87M

Current Ratio (TTM)

TNXP6.61x

VTVT12.48x

Quick Ratio (TTM)

TNXP6.13x

VTVT12.42x

Debt/Equity (TTM)

TNXP0.00x

VTVT0.00x

Debt/Assets (TTM)

TNXP0.0%

VTVT0.0%

Interest Coverage (TTM)

TNXPN/A

VTVTN/A

Net Debt/EBITDA (TTM)

TNXP0.00x

VTVT0.00x

Beta

TNXP1.87

VTVT0.23

52W Performance

TNXP-67.5%

VTVT38.3%

YTD Performance

TNXP-55.9%

VTVT-21.3%

% from 52W High

TNXP-68.3%

VTVT-29.1%

% from 52W Low

TNXP3.0%

VTVT59.9%

Asset Turnover (TTM)

TNXP0.11x

VTVT0.37x

FCF Yield (TTM)

TNXP-135.9%

VTVT-13.6%

Earnings Yield (TTM)

TNXP-137.2%

VTVT-3.9%

Dividend Yield (TTM)

TNXPN/A

VTVTN/A

Rule of 40

TNXP-347.3

VTVT216,554.5

EV/GP/RG

TNXPN/A

VTVTN/A

Ticker research

View TNXP research View VTVT research

Metric	TNXP Tonix Pharmaceuticals Holding Corp	VTVT vTv Therapeutics Inc
Market & Valuation
Market Cap	$116M	$123M
Enterprise Value	$-60M	$36M
Price	$7.30	$31.18
P/E Ratio	N/A	N/A
P/S Ratio	4.00x	3.33x
EV/Sales	-2.06x	0.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.69x	1.53x
P/FCF Ratio	N/A	N/A
EV/FCF	0.38x	-2.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.39x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$37M
Revenue Growth (YoY)	196.0%	216600.0%
Forward Rev Growth	101.6%	-97.3%
Profitability
Gross Margin (TTM)	83.8%	0.0%
Operating Margin (TTM)	0.0%	63.1%
EBITDA Margin (TTM)	-561.1%	-25.1%
Net Margin (TTM)	-548.6%	-12.9%
FCF Margin (TTM)	-543.3%	-45.5%
Net Income (TTM)	$-160M	$-5M
FCF (TTM)	$-158M	$-17M
EPS (TTM)	-$9.60	-$0.38
ROE (TTM)	-6899.0%	-627.0%
ROA (TTM)	-6132.0%	-506.0%
ROIC (TTM)	-6899.0%	-626.0%
Financial Health
Cash	$176M	$87M
Debt	$0	$0
Net Cash/Debt	$176M	$87M
Current Ratio (TTM)	6.61x	12.48x
Quick Ratio (TTM)	6.13x	12.42x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.23
52W Performance	-67.5%	38.3%
YTD Performance	-55.9%	-21.3%
% from 52W High	-68.3%	-29.1%
% from 52W Low	3.0%	59.9%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.37x
FCF Yield (TTM)	-135.9%	-13.6%
Earnings Yield (TTM)	-137.2%	-3.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-347.3	216,554.5
EV/GP/RG	N/A	N/A
Ticker research	View TNXP research	View VTVT research

Valuation

P/S Ratio

VTVT

3.33x

TNXP

4.00x

EV/FCF

VTVT

-2.16x

TNXP

0.38x

Growth & revenue

Revenue Growth TTM

VTVT

216600.0%

TNXP

196.0%

Forward Revenue Growth

TNXP

101.6%

VTVT

-97.3%

Profitability & performance

Gross Margin

TNXP

83.8%

VTVT

0.0%

ROE

VTVT

-627.0%

TNXP

-6899.0%

FCF Yield %

VTVT

-13.6%

TNXP

-135.9%

52-Week Performance

VTVT

38.3%

TNXP

-67.5%

Detailed metrics comparison

TNXP

Tonix Pharmaceuticals Holding Corp

VTVT

vTv Therapeutics Inc

Market Cap

TNXP$116M

VTVT$123M

Enterprise Value

TNXP$-60M

VTVT$36M

Price

TNXP$7.30

VTVT$31.18

P/E Ratio

TNXPN/A

VTVTN/A

P/S Ratio

TNXP4.00x

VTVT3.33x

EV/Sales

TNXP-2.06x

VTVT0.98x

EV/EBITDA

TNXP0.00x

VTVT0.00x

P/B Ratio

TNXP0.69x

VTVT1.53x

P/FCF Ratio

TNXPN/A

VTVTN/A

EV/FCF

TNXP0.38x

VTVT-2.16x

PEG Ratio

TNXPN/A

VTVTN/A

Forward P/E (NTM)

TNXPN/A

VTVTN/A

Forward P/S (NTM)

TNXP1.39x

VTVTN/A

Revenue (TTM)

TNXP$29M

VTVT$37M

Revenue Growth (YoY)

TNXP196.0%

VTVT216600.0%

Forward Rev Growth

TNXP101.6%

VTVT-97.3%

Gross Margin (TTM)

TNXP83.8%

VTVT0.0%

Operating Margin (TTM)

TNXP0.0%

VTVT63.1%

EBITDA Margin (TTM)

TNXP-561.1%

VTVT-25.1%

Net Margin (TTM)

TNXP-548.6%

VTVT-12.9%

FCF Margin (TTM)

TNXP-543.3%

VTVT-45.5%

Net Income (TTM)

TNXP$-160M

VTVT$-5M

FCF (TTM)

TNXP$-158M

VTVT$-17M

EPS (TTM)

TNXP-$9.60

VTVT-$0.38

ROE (TTM)

TNXP-6899.0%

VTVT-627.0%

ROA (TTM)

TNXP-6132.0%

VTVT-506.0%

ROIC (TTM)

TNXP-6899.0%

VTVT-626.0%

Cash

TNXP$176M

VTVT$87M

Debt

TNXP$0

VTVT$0

Net Cash/Debt

TNXP$176M

VTVT$87M

Current Ratio (TTM)

TNXP6.61x

VTVT12.48x

Quick Ratio (TTM)

TNXP6.13x

VTVT12.42x

Debt/Equity (TTM)

TNXP0.00x

VTVT0.00x

Debt/Assets (TTM)

TNXP0.0%

VTVT0.0%

Interest Coverage (TTM)

TNXPN/A

VTVTN/A

Net Debt/EBITDA (TTM)

TNXP0.00x

VTVT0.00x

Beta

TNXP1.87

VTVT0.23

52W Performance

TNXP-67.5%

VTVT38.3%

YTD Performance

TNXP-55.9%

VTVT-21.3%

% from 52W High

TNXP-68.3%

VTVT-29.1%

% from 52W Low

TNXP3.0%

VTVT59.9%

Asset Turnover (TTM)

TNXP0.11x

VTVT0.37x

FCF Yield (TTM)

TNXP-135.9%

VTVT-13.6%

Earnings Yield (TTM)

TNXP-137.2%

VTVT-3.9%

Dividend Yield (TTM)

TNXPN/A

VTVTN/A

Rule of 40

TNXP-347.3

VTVT216,554.5

EV/GP/RG

TNXPN/A

VTVTN/A

Ticker research

View TNXP research View VTVT research

Metric	TNXP Tonix Pharmaceuticals Holding Corp	VTVT vTv Therapeutics Inc
Market & Valuation
Market Cap	$116M	$123M
Enterprise Value	$-60M	$36M
Price	$7.30	$31.18
P/E Ratio	N/A	N/A
P/S Ratio	4.00x	3.33x
EV/Sales	-2.06x	0.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.69x	1.53x
P/FCF Ratio	N/A	N/A
EV/FCF	0.38x	-2.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.39x	N/A
Revenue & Growth
Revenue (TTM)	$29M	$37M
Revenue Growth (YoY)	196.0%	216600.0%
Forward Rev Growth	101.6%	-97.3%
Profitability
Gross Margin (TTM)	83.8%	0.0%
Operating Margin (TTM)	0.0%	63.1%
EBITDA Margin (TTM)	-561.1%	-25.1%
Net Margin (TTM)	-548.6%	-12.9%
FCF Margin (TTM)	-543.3%	-45.5%
Net Income (TTM)	$-160M	$-5M
FCF (TTM)	$-158M	$-17M
EPS (TTM)	-$9.60	-$0.38
ROE (TTM)	-6899.0%	-627.0%
ROA (TTM)	-6132.0%	-506.0%
ROIC (TTM)	-6899.0%	-626.0%
Financial Health
Cash	$176M	$87M
Debt	$0	$0
Net Cash/Debt	$176M	$87M
Current Ratio (TTM)	6.61x	12.48x
Quick Ratio (TTM)	6.13x	12.42x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.87	0.23
52W Performance	-67.5%	38.3%
YTD Performance	-55.9%	-21.3%
% from 52W High	-68.3%	-29.1%
% from 52W Low	3.0%	59.9%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.37x
FCF Yield (TTM)	-135.9%	-13.6%
Earnings Yield (TTM)	-137.2%	-3.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-347.3	216,554.5
EV/GP/RG	N/A	N/A
Ticker research	View TNXP research	View VTVT research